Seroquel (Quetiapine Fumarate) InPractice Evaluation Programme
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT00921362
- Lead Sponsor
- AstraZeneca
- Brief Summary
Patients eligible for entry into the study have a diagnosis of schizophrenia defined by Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria and of a chronic or sub-chronic nature.The primary purpose of the study is to observe symptoms changes over 6 months in schizophrenia in patients treated with Seroquel; additionally disease severity and treatment compliance are followed
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1387
Inclusion Criteria
- To assess at baseline and after treatment administration the severity of the illness in patients with schizophrenia, using the scores obtained after the application of the CGI scale
- To assess the changes in symptoms of patients treated with Seroquel for 24 weeks, using BPRS (Brief Psychiatry Rating Scale) as measuring tool
Exclusion Criteria
- All the patients who have a known hypersensitivity to Seroquel /quetiapine or any of its excipients will not be included in this study.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Brief Psychiatric Rating Scale - BPRS Monthly at every clinic visit- 7 times
- Secondary Outcome Measures
Name Time Method Clinical Global Impression Severity of Illness Monthly/ at every clinic visit-7 times CGI-S Clinical Global Impression Improvement CGI -I Monthly/ at every clinic visit except first visit- 6 times